Actinogen advances Alzheimer's and depression treatments, strengthens financial position

Actinogen Medical's annual report 2025 highlights substantial progress in its clinical programs, particularly the pivotal XanaMIA phase 2b/3 AD clinical trial, which passed its 100th participant milestone. Interim analysis for this trial is scheduled for January 2026, with final results expected in Q4 2026. The company also announced positive depression results from the XanaCIDD phase 2a trial, reinforcing Xanamem's efficacy in major depressive disorder.

Financially, Actinogen strengthened its position with an $11.1 million capital-raising and received a $9.0 million R&D tax incentive rebate in October 2024. Total cash and cash equivalents stood at $16,504,230 as of June 30, 2025. The company reported a net loss after tax of $(14,732,263) for the year ended June 30, 2025, compared to $(13,044,282) in 2024.

Commercialization efforts are underway with the appointment of a chief commercial officer and ongoing market research. Manufacturing has scaled up with the production of a 15kg batch of drug substance, preparing for future commercial quantity production. The company continues to engage with regulatory bodies like the FDA and EMA to define clear pathways for marketing approval.